Asset profile
Emestedastat · Xanamem
Small molecule
Evidence outlook · registrational
Alzheimer's Disease: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2026-10) has passed without a status update. Check News for topline announcements.
XanADu (NCT02727699): Randomized, triple-masked, placebo-controlled phase 2 in mild Alzheimer's dementia (185 participants). Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.
Also in development:Major Depressive Disorder · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 118 same-indication; 42 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Emestedastat (Xanamem): this drug | Phase 2/3 | Small molecule | 11-beta-HSD1 | ||
| Clofutriben | Phase 2 | Small molecule | 11-beta-HSD1 | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | ||
| Lecanemab (Leqembi) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | ||
| Olanzapine / Fluoxetine (Symbyax) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor) | ||
| Solriamfetol (Sunosi) | Approved | Small molecule | Dopamine/norepinephrine transporter | ||
| Vortioxetine (Trintellix) | Approved | Small molecule | Serotonin transporter + multiple 5-HT receptors | ||
| Xanomeline / Trospium Chloride (Cobenfy) | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| ACP-204 | Phase 3 | Small molecule | Serotonin 5-HT2A receptor (antagonist / inverse agonist) |
…and 104 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.